Article Listing - Double dose of woes for Eli Lilly, as it drops Ph III AD drug semagacestat and FDA panel could say no to expanding use of Cymbalta

DRUGS AND SWEDEN'S HEALTH BILL

6 April 1992

Sales of pharmaceutical products in Sweden totaled 10 billion krone ($1.6 billion) in 1990, an increase of 1 billion krone...

MAINTENANCE ULCER THERAPY CUT URGED

6 April 1992

A team of UK gastroenterologists have called for physicians to stop treating duodenal ulcer patients with maintenance H2 antagonist therapy....

WELLCOME SHARE FLOAT "MANAGERS"

6 April 1992

Following the recent announcement of its decision to float a further bank of shares in Wellcome plc, the Wellcome Trust...

BLOOD BANKING AND PLASMA PRODUCTS

6 April 1992

The world market for blood banking and plasma products was valued at $2.5 billion in 1990, and is expected to...

AUSTRALIAN VACCINE RESEARCH

6 April 1992

The Walter and Eliza Hall Institute of Medical research in Melbourne, Australia, is to set up a commercial joint venture...

MGI PHARMA'S SALAGEN

6 April 1992

MGI Pharma has gained orphan drug status from the US Food and Drug Administration for Salagen (pilocarpine), to treat dry...

NEW EDITOR OF D&TB

6 April 1992

Joe Collier, reader and consultant in clinical pharmacology at St George's Hospital Medical School, London, has been appointed editor of...

New Swiss Hospital Costs Program

6 April 1992

The Swiss Federal Council has come out in support of the need for severe measures to combat increasing health care...

SANOFI 1991 NET INCOME UP 12.1%

6 April 1992

For France's Elf Sanofi, earnings progressed satisfactorily in 1991 despite the adverse operating environment (the world economic situation including the...

DEPRESSION: THE COST TO SOCIETY

6 April 1992

The costs of depression to the National Health Service in the UK are L 333 million per year, according to...

Showing 94631-94640 of 95579 articles